A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
Clinical trial NCT06556394 · RECRUITING
Trial details
- NCT number
- NCT06556394
- Sponsor
- Ractigen Therapeutics.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-24
- Primary completion
- 2026-02-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.